JP2024525613A5 - - Google Patents
Info
- Publication number
- JP2024525613A5 JP2024525613A5 JP2024500492A JP2024500492A JP2024525613A5 JP 2024525613 A5 JP2024525613 A5 JP 2024525613A5 JP 2024500492 A JP2024500492 A JP 2024500492A JP 2024500492 A JP2024500492 A JP 2024500492A JP 2024525613 A5 JP2024525613 A5 JP 2024525613A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- oligonucleotide
- optionally
- sequence
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220016P | 2021-07-09 | 2021-07-09 | |
| US63/220,016 | 2021-07-09 | ||
| US202263316466P | 2022-03-04 | 2022-03-04 | |
| US63/316,466 | 2022-03-04 | ||
| PCT/US2022/073541 WO2023283624A2 (en) | 2021-07-09 | 2022-07-08 | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525613A JP2024525613A (ja) | 2024-07-12 |
| JP2024525613A5 true JP2024525613A5 (enExample) | 2025-07-17 |
Family
ID=84802101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500492A Pending JP2024525613A (ja) | 2021-07-09 | 2022-07-08 | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240368296A1 (enExample) |
| EP (1) | EP4366741A4 (enExample) |
| JP (1) | JP2024525613A (enExample) |
| KR (1) | KR20240035824A (enExample) |
| AU (1) | AU2022309238A1 (enExample) |
| CA (1) | CA3226367A1 (enExample) |
| IL (1) | IL309912A (enExample) |
| MX (1) | MX2024000492A (enExample) |
| WO (1) | WO2023283624A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| TW202442246A (zh) | 2023-04-27 | 2024-11-01 | 美商薩羅塔治療公司 | 用於治療慢性腎病之反義寡聚物 |
| WO2024233303A1 (en) * | 2023-05-05 | 2024-11-14 | Biomarin Pharmaceutical Inc. | Dystrophin exon skipping oligonucleotides |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| WO2025085810A2 (en) | 2023-10-18 | 2025-04-24 | Sarepta Therapeutics, Inc. | Antisense oligomers for treatment of centronuclear myopathies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005058244A2 (en) * | 2003-12-15 | 2005-06-30 | Alexion Pharmaceuticals, Inc. | Novel anti-dc-sign antibodies |
| EP2933332A1 (en) * | 2004-06-28 | 2015-10-21 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| WO2008073300A2 (en) * | 2006-12-08 | 2008-06-19 | Lexicon Pharmaceuticals, Inc. | Monoclonal antibodies against angptl3 |
| BR112013014527A2 (pt) * | 2010-12-20 | 2017-03-07 | Genentech Inc | anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, uso do imunoconjugado, método para tratamento de um indivíduo que tem um câncer positivo para mesotelina, para inibição de proliferação de uma célula positiva para mesotelina, para detecção de mesotelina humana em uma amostra biológica e para detectar um câncer positivo para mesotelina |
| RU2014109038A (ru) * | 2011-08-23 | 2015-09-27 | Рош Гликарт Аг | Антитела к хондроитинсульфат протеогликану меланомы |
| AU2015225496A1 (en) * | 2014-03-03 | 2016-10-13 | Sujata ACHARJEE | Chimeric dystrophin-VSV-G-protein to treat dystrophinopathies |
| AR099625A1 (es) * | 2014-03-21 | 2016-08-03 | Lilly Co Eli | Anticuerpos de il-21 |
| JP7015244B2 (ja) * | 2016-03-22 | 2022-02-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | プロテアーゼ活性化ｔ細胞二重特異性分子 |
| MX2020003130A (es) * | 2017-09-22 | 2020-09-25 | Avidity Biosciences Inc | Composiciones y metodos de induccion de salto de exon en acidos nucleicos-polipeptidos. |
| CA3108282A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| IL280536B2 (en) * | 2018-08-02 | 2024-12-01 | Dyne Therapeutics Inc | Complexes targeting transferrin receptor and uses thereof |
| WO2020219820A1 (en) * | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| JP7780691B2 (ja) * | 2020-01-10 | 2025-12-05 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| CA3163608A1 (en) * | 2020-01-10 | 2021-07-15 | Romesh R. Subramanian | Muscle-targeting complexes and uses thereof |
| MX2023000984A (es) * | 2020-07-23 | 2023-05-03 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias. |
-
2022
- 2022-07-08 AU AU2022309238A patent/AU2022309238A1/en active Pending
- 2022-07-08 IL IL309912A patent/IL309912A/en unknown
- 2022-07-08 US US18/577,452 patent/US20240368296A1/en active Pending
- 2022-07-08 KR KR1020247004338A patent/KR20240035824A/ko active Pending
- 2022-07-08 CA CA3226367A patent/CA3226367A1/en active Pending
- 2022-07-08 WO PCT/US2022/073541 patent/WO2023283624A2/en not_active Ceased
- 2022-07-08 MX MX2024000492A patent/MX2024000492A/es unknown
- 2022-07-08 EP EP22838594.4A patent/EP4366741A4/en active Pending
- 2022-07-08 JP JP2024500492A patent/JP2024525613A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024525613A5 (enExample) | ||
| JP2024525611A5 (enExample) | ||
| JP2024525612A5 (enExample) | ||
| JP2024527362A5 (enExample) | ||
| JP2024525610A5 (enExample) | ||
| IL309912A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309937A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309935A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309911A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309909A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JP2023510350A5 (enExample) | ||
| JP2023535073A5 (enExample) | ||
| JP7803926B2 (ja) | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 | |
| US20240325558A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| US11771776B2 (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| US20230088865A1 (en) | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy | |
| JP2023509793A5 (enExample) | ||
| JP2024540199A (ja) | ジストロフィノパチーを処置するための筋標的化複合体 | |
| JP2024540199A5 (enExample) | ||
| JP2024524222A5 (enExample) | ||
| JP2023512441A5 (enExample) | ||
| IL304048A (en) | Muscle targeting complexes and their uses for the treatment of myotonic dystrophy | |
| IL309936A (en) | Muscle targeting complexes and formulations for the treatment of dystrophinopathy | |
| JP2024501872A5 (enExample) | ||
| JP2026503873A (ja) | Ｄｍｄ遺伝子のエクソン４５をスキップするための筋肉標的化複合体およびその使用 |